About

Ledipasvir/Sofosbuvir is a fixed-dose combination direct-acting antiviral (DAA) medication specifically designed for the treatment of chronic Hepatitis C virus (HCV) infection. Ledipasvir is an HCV NS5A inhibitor, which is crucial for viral replication and assembly. Sofosbuvir is a nucleotide analog NS5B polymerase inhibitor, directly targeting the viral RNA polymerase enzyme responsible for replicating the HCV genome. By inhibiting these two distinct viral proteins, the combination effectively blocks multiple steps in the HCV life cycle, leading to high rates of sustained virologic response (SVR) and often achieving a cure for chronic HCV infection across various genotypes, particularly genotype 1, 4, 5, and 6. This regimen represents a significant advancement in HCV therapy, offering a highly effective, well-tolerated, and interferon-free treatment option.

Uses

Treatment of chronic Hepatitis C virus (HCV) genotype 1 infection.
Treatment of chronic Hepatitis C virus (HCV) genotype 4 infection.
Treatment of chronic Hepatitis C virus (HCV) genotype 5 infection.
Treatment of chronic Hepatitis C virus (HCV) genotype 6 infection.

Directions For Use

Take one tablet orally once daily, with or without food, for the duration prescribed by your healthcare provider.

Benefits

Achieves high cure rates for chronic Hepatitis C.
Offers a short treatment duration compared to older therapies.
Generally well-tolerated with a favorable safety profile.
Provides an interferon-free and ribavirin-free regimen.
Effective across multiple HCV genotypes.
Prevents progression of liver damage and complications.

Side Effects

Fatigue
Headache
Nausea
Diarrhea
Insomnia
Asthenia (weakness)
Irritability
Skin rash
Pruritus (itching)
Myalgia (muscle pain)
Arthralgia (joint pain)
Decreased appetite

Safety Measures

Alcohol - Avoid alcohol completely, as it can worsen liver disease and interfere with treatment efficacy.
Pregnancy - Not recommended during pregnancy due to potential risks; effective contraception is advised during treatment.
Breastfeeding - Not recommended as it is unknown if the components are excreted in human milk.
Liver - Generally safe, but monitor closely in patients with decompensated cirrhosis.
Kidney - Use with caution in severe renal impairment; not recommended for patients with eGFR <30 mL/min.
Lung - No specific contraindications or precautions related to lung conditions.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.

Shipping & Location